Global Fluorescein Angiography Market by Technology (Digital, Analog), by Product (Disposables, Device, Accessories) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global fluorescein-angiography market was valued at USD 498.8 millions in 2019. It is expected to grow at 2.7% compound annual growth rate (CAGR), between 2020 and 2027. Fluorescein angiography is driven by the increasing prevalence of eye diseases and the growing demand for early diagnosis. VISION 2020, a WHO global campaign to raise awareness about blindness and the long-term commitment of governments to eliminating it, is a global campaign. International decision-makers and non-governmental organizations must be convinced that the human and financial resources required to eliminate blindness are sound and returnable investments.

The market for ophthalmology is primarily driven by lifestyle and age-related diseases like macular degeneration, cataracts, macular degeneration, and diabetic retina. Fluorescein angiography is expected to grow due to the increasing incidence of eye-related conditions and the growing geriatric population. Macular degeneration, which is often associated with aging, is the main cause of eye-related disorders. It causes damage to central and sharp sight.

Macular degeneration, which accounts for nearly 50.0% of all visual impairments worldwide, is the leading cause of blindness. The market is also being driven by the growing burden of glaucoma worldwide. The Glaucoma Research Foundation states that glaucoma is second in blindness worldwide after cataracts.

Globally, 8.4 million people were blinded by glaucoma in 2010. This number is projected to rise to 11.1 million by 2020. The risk of developing blindness is greater for people with glaucoma who live in the poorest countries. The American Academy of Ophthalmology predicts that 111 million people will have glaucoma by 2040. Asia and Africa are the most affected regions.

Product Insights

In 2019, the device segment held a dominant revenue share at 66.1% in fluorescein-angiography market. The segment is expected to grow because of its higher specificity and lower false positive rates than the optical coherent tomography (OCT), particularly in the diagnosis for Wet Age-Related Macular Degeneration. These devices can also be used to monitor the effectiveness of certain treatment methods such as Anti-Vascular Endothelial Growth Factor in wAMD.

Fluorescein angiography is likely to grow because of the frequent launches of integrated devices that can perform multiple tests in one system. NIDEK, for example, announced in August 2019 the multimodal ophthalmic tech-Mirante. This device can perform fluorescein, OCT, indocyanine, green angiography and capture high-quality retinal pictures in one device. These technologies offer many advantages, including the ability to increase diagnostic capabilities for physicians and a reduction in cost and floor space.

Technology Insights

In 2019, the digital segment accounted for 98.0% of fluorescein-angiography's market share. The digital technology provides high-resolution images of the retinal structures, which is a significant advantage over conventional methods such as contrast films. You can adjust the brightness or contrast of the images to highlight specific details or zoom in on areas of concern.

The digital imaging system has made it easier to store and retrieve pictures. This allows for quick comparisons of images during diagnosis and treatment. Many developed countries like the U.S., Canada and other countries are moving to paperless healthcare. They place more emphasis on electronic medical records to avoid any discrepancies in reimbursement costs. These factors will drive further growth in the segment.

Application Insights

In 2019, the macular degeneration segment accounted for 38.1% of all revenue. Due to the dramatic rise in diabetes-related eye diseases, the diabetic retinopathy segment is expected to grow at the highest rate during the forecast period. The International Association for Prevention of Blindness estimates that there will be more than 642 million diabetics worldwide by 2040. Around 35.0% of these people are likely to develop diabetic retinopathy.

The introduction of AI in ocular diagnostics will likely boost the growth market for fluorescein angiography. In January 2019, FDA approved the use of an AI system in a fundus camera called TRC–NW400 (Topcon Corporation), for diagnosing diabetic retinopathy. This allows quick delivery of reports without the need to consult an ophthalmologist. This would reduce the healthcare staff's workload and allow them to concentrate on their most important tasks.

Regional Insights

With a market share of 48.8%, North America was the dominant country in fluorescein-angiography. Due to the high number of patients with diabetic retinopathy and the large volume of procedures, North America dominated fluorescein angiography market in 2019. The National Eye Institute (NIH) predicts that the number of people suffering from diabetic retinopathy will increase from 7.7 millions in 2010 to 14.6million in 2050. Fundus cameras are used to detect diabetic retinopathy early.

Market players continue to develop and launch advanced fundus cameras. Carl Zeiss, for instance, introduced two next-generation nonmydriatic VISUCAM 524 cameras and VISUCAM 234 cameras in November 2015 at the American Academy of Ophthalmology, Las Vegas. These fundus cameras can be used to diagnose many retinal diseases. Fluorescein angiography will see an increase in demand due to the introduction of digital cameras and hybrid cameras.

Market Share Insights & Key Companies

To maintain their market share for fluorescein-angiography, market players have adopted several strategies to increase product launches, distribute agreements and innovate products. Topcon's Maestro2Automated OCT/Fundus Camera was launched in August 2019. This launch will likely increase the company's ophthalmic product line. Carl Zeiss Meditec introduced Clarus 500 ultrawidefield fundus imaging system in September 2017. This aids in early disease diagnosis, and better patient management. The market leader in fluorescein angiography is:

• Carl Zeiss Meditec, Inc.

• NIDEK Co., Ltd.

• Kowa Company Ltd.

• Topcon Medical Systems, Inc.

• Optomed Oy (Ltd.)

• CenterVue SpA

• Canon, Inc.

Up Market Research published a new report titled “Fluorescein Angiography Market research report which is segmented by Technology (Digital, Analog), by Product (Disposables, Device, Accessories), By Players/Companies CenterVue SpA, Optomed Oy (Ltd), Carl Zeiss Meditec Inc, Kowa Company Ltd, Canon Inc, Topcon Medical Systems Inc, NIDEK Co Ltd”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Fluorescein Angiography Market Report Segments:

The market is segmented by Technology (Digital, Analog), by Product (Disposables, Device, Accessories).

Fluorescein Angiography Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Fluorescein Angiography Market

Overview of the regional outlook of the Fluorescein Angiography Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Fluorescein Angiography Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Fluorescein Angiography Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Digital

                2. Analog

                1. Disposables

                2. Device

                3. Accessories

8. Market scenario by region, sub-region, and country.
9. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
10. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
11. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Fluorescein Angiography Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Fluorescein Angiography Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.